Cisplatin tnbc

Author: kqmx

August undefined, 2024

WebJun 3, 2013 · Triple-negative breast cancer (TNBC), which is defined as estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) –negative disease, accounts for 11% to 17% of all breast cancers. 1,2 The incidence of this type of breast cancer is greater among young patients and African American patients. 2 … WebOur result demonstrates the lack of TGF-β induced TMEPAI on the TNBC response to cisplatin. This might be due to the overexpression of Islet-1 in TNBC patients. 47 Islet-1 overexpression was reported to reduce TNBC cell response to cisplatin. 47,48 In the cells that have limited response to cisplatin, the role of TMEPAI is not prominent.

Cisplatin-resistant triple-negative breast cancer subtypes: multiple ...

WebJan 3, 2024 · Triple Negative Breast Cancer: Drug: Cisplatin Drug: Nab-paclitaxel Drug: Pembrolizumab Drug: Olaparib: Phase 2: Detailed Description: TNBC is a hard-to-treat disease requiring continuous administration of drugs, necessitating further exploration of optimal maintenance strategy. However, there are currently no standard maintenance … WebSep 18, 2024 · National Center for Biotechnology Information eastern hemisphere geography lessons

Special Issue "Metal-Based Complexes in Cancer Treatment"

WebJul 12, 2024 · Platinum agents, such as carboplatin and cisplatin, have been recommended in combination with gemcitabine for the treatment of metastatic triple negative breast cancer (TNBC). Here the authors ... WebTriple-negative breast cancer (TNBC) is the most dangerous subtype with the worst therapeutic prognosis and outcomes due to the absence of receptors for estrogen, progesterone, and HER2. Chemotherapy is the standard treatment for TNBC, and cisplatin is widely used in the clinical management of TNBC [1–3]. Therefore, the loss of … WebMar 17, 2024 · Cisplatin treatment had a profound immunological effect by significantly reducing the levels of the primary tumor cytokines B-cell activating factor (BAFF) and interleukin (IL)-1β compared to... eastern hemisphere from space

Metformin overcomes resistance to cisplatin in triple-negative breast ...

Molecules Free Full-Text The Challenging Treatment of Cisplatin ...

WebJun 22, 2024 · Cisplatin (DDP) was reported to improve pathological complete response (pCR) rates in triple-negative breast cancer (TNBC) patients, however, the molecular mechanism still remains largely unknown. Emerging evidence suggested that some chemotherapeutic drugs played anti-tumor effects by inducing cell pyroptosis. WebJan 14, 2024 · Cisplatin has been widely used in the treatment of a various types of cancers including triple-negative breast cancer (TNBC) by damaging DNA and inducing apoptosis. However, its anti-cancer effects are often limited due to chemo-resistance, which is one of the main reasons causing cancer relapse and metastasis. eastern hemisphere explorerWebFeb 15, 2024 · A total of 34 patients were treated with adavosertib and cisplatin as first- or second-line therapy for mTNBC. The endpoint was not met, but the objective response rate was 26% and median progression-free survival was 4.9 months. eastern hemisphere facts

"WebFeb 7, 2024 · Cisplatin is an old, platinum based anticancer drug that kills cancer cells by damaging their DNA. Its cytotoxic (cell-killing) properties were discovered by accident in … " - Cisplatin tnbc

Cisplatin tnbc

Effect of miR-133b on progression and cisplatin resistance of …

WebJun 6, 2024 · Patients with clinical stage II or III TNBC with ≥ 1 cm RD in the breast post-NAC were randomly assigned to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of … WebMay 25, 2024 · Methods: Patients (pts) with metastatic TNBC or g BRCA1/2- associated MBC, who had received < 1 line of prior therapy were treated with cisplatin (75mg/m2) …

Did you know?

WebHypoxia can induce chemoresistance, which is a significant clinical obstacle in cancer therapy. Here, we assessed development of hypoxia-induced chemoresistance (HICR) against free versus polymeric cisplatin micelles in a triple negative breast cancer cell line, MDA-MB-231. We then explored two strategies for the modulation of HICR against … WebOct 22, 2024 · Cisplatin is widely used to treat solid tumors, including breast, testicular, and ovarian cancers [ 7 ]. Cisplatin exerts its anticancer effects by inducing DNA double …

WebSep 22, 2010 · Cisplatin also promotes apoptosis in TNBC by disrupting a complex between the p53 family members ΔNp63 and TAp73 that is present selectively in TNBC with mutant TP53 . Specifically, cisplatin induces c-Abl-mediated phosphorylation of TAp73, which releases pro-apoptotic TAp73 from the inhibitory complex and triggers apoptosis. ... WebNational Center for Biotechnology Information

WebMar 31, 2024 · The present study evaluated the in vitro and in vivo anticancer effects of Pd 2 Spm compared to the reference metal-based drug cisplatin. Triple-negative breast cancer MDA-MB-231 cells, non-cancerous MCF-12A breast cells and chorioallantoic membrane (CAM) assay were used for antiproliferative, antimigratory and antiangiogenic studies.

WebMar 22, 2024 · Here, we review the current role of cisplatin and carboplatin in the treatment of early stage and advanced triple-negative breast cancer (TNBC), and the use of …

WebMar 17, 2024 · Here, we investigated the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for triple … cuffs with beltWebOct 28, 2024 · A phase I study (NCT01445418) investigated olaparib combined with carboplatin in metastatic or recurrent TNBC patients with no germline BRCA mutation or with BRCAPro scores < 10% and negative family history. The objective response rate was 22%, with 1 patient having complete response. eastern hemisphere definition geographyWebOct 7, 2010 · The investigators hypothesized that paclitaxel combined with cisplatin is more sensitive to triple negative breast cancer compared with CEF followed by docetaxel. Detailed Description: Eligibility Female adults (18-70 years old) are eligible if they had histologically confirmed primary breast cancer. eastern hemisphere facts for kidsWebFeb 26, 2024 · This study demonstrates that MYSM1 is required for sensitizing TNBC cells to cisplatin by enhancing cell apoptosis. The fundamental mechanism entails the depletion of RSK3, which blocks the... cuffs with a beltWebJul 22, 2024 · Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side … eastern hemisphere in the 1500\\u0027sWebCisplatin is a chemotherapy drug which is used to treat cancers including: sarcoma, small cell lung cancer, germ cell tumors, lymphoma, and ovarian cancer. While it is often … eastern hemisphere in the 1500\u0027sWebJun 15, 2024 · Introduction. As one of the main causes of female deaths, breast cancer (BC) is a heterogeneous tumor with different subtypes [1,2].Triple negative breast cancer … cuffs weights